Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Probenecid
Drug: Empagliflozin (BI 10773)
Drug: Empagliflozin
Drug: Rifampicin

First Posted Date: 2012-07-06

Last Posted Date: 2014-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01634100

Locations: 🇩🇪
1245.83.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Tiotropium high dose QD
Drug: Tiotropium low dose QD
Drug: Placebo

First Posted Date: 2012-07-06

Last Posted Date: 2016-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 403

Registration Number: NCT01634139

Locations: 🇬🇹
205.445.50205 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala
🇱🇻
205.445.37103 Boehringer Ingelheim Investigational Site, Riga, Latvia
🇱🇹
205.445.37003 Boehringer Ingelheim Investigational Site, Vilnius, Lithuania

and more 76 locations

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: tiotropium-bromide
Drug: placebo

First Posted Date: 2012-07-06

Last Posted Date: 2015-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 102

Registration Number: NCT01634113

Locations: 🇺🇸
205.443.12003 Boehringer Ingelheim Investigational Site, Columbia, Missouri, United States
🇱🇻
205.443.05001 Boehringer Ingelheim Investigational Site, Balvi, Latvia
🇧🇪
205.443.01002 Boehringer Ingelheim Investigational Site, Brussel, Belgium

and more 30 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Phase 1

Completed

Conditions: Healthy
Asthma

Interventions: Drug: BI 1021958 qd
Drug: Placebo to BI 1021958 qd
Drug: BI 1021958 bid
Drug: Placebo to BI 1021958 bid

First Posted Date: 2012-06-28

Last Posted Date: 2013-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 84

Registration Number: NCT01629849

Locations: 🇩🇪
1310.2.1 Boehringer Ingelheim Investigational Site, Gauting, Germany

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib

First Posted Date: 2012-06-14

Last Posted Date: 2022-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 752

Registration Number: NCT01619085

Locations: 🇧🇪
Yvoir - UNIV UCL de Mont-Godinne, Yvoir, Belgium
🇨🇱
Instituto Nacional del Tórax, Santiago de Chile, Chile
🇨🇳
Peking University People's Hospital, Beijing, China

and more 167 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2012-06-04

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT01611311

Locations: 🇩🇪
1289.17.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

Phase 3

Withdrawn

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 201335
Drug: PegIFN/RBV

First Posted Date: 2012-05-31

Last Posted Date: 2013-02-26

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01608737

Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 695502
Drug: bevacizumab

First Posted Date: 2012-05-30

Last Posted Date: 2019-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 91

Registration Number: NCT01608087

Locations: 🇳🇿
1302.1.002 Boehringer Ingelheim Investigational Site, Auckland NZ, New Zealand
🇳🇿
1302.1.001 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 207127 NA

First Posted Date: 2012-05-25

Last Posted Date: 2016-03-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT01605461

Locations: 🇺🇸
1241.22.001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ticagrelor
Drug: dabigatran etexilate

First Posted Date: 2012-05-10

Last Posted Date: 2013-08-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01595854

Locations: 🇩🇪
1160.141.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy